Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line

Anti-Cancer Drugs

Volumn 28, Issue 4, 2017, Pages 446-456

  Zhou, Zhongping ^a   Tang, Miaomiao ^a   Liu, Yi ^a   Zhang, Zhuyi ^a   Lu, Rongzhu ^a   Lu, Jian ^a,b  

^a JIANGSU UNIVERSITY   (China)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Akt; apigenin; invasion; lung cancer; migration; proliferation

Indexed keywords

APIGENIN; GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; HEF1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ONCOPROTEIN;

A-549 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASSAY; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSWELL ASSAY; WESTERN BLOTTING; WOUND HEALING ASSAY; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR INVASION;

A549 CELLS; APIGENIN; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 85010910598     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000479     Document Type: Article

References (68)

1. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001; 90:157-177.
2. P D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007; 30:233-245.
3. Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 2001; 287:914-920.
4. Kim HY, Kim OH, Sung MK. Effects of phenol-depleted and phenol-rich diets on blood markers of oxidative stress, and urinary excretion of quercetin and kaempferol in healthy volunteers. J Am Coll Nutr 2003; 22:217-223.
5. Eun Jeong C, Gun-Hee K. Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J Clin Biochem Nutr 2009; 44:260-265.
6. Tzong-Der W, Ming-Ching K, Jen-Kun L. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 2004; 279:4479-4489.
7. Wei-Jiunn L, Wen-Kang C, Chau-Jong W, Wea-Lung L, Tsui-Hwa T. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 2008; 226:178-191.
8. Parminder K, Sanjeev S, Sanjay G. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis 2008; 29:2210-2217.
9. Shukla S, Gupta S. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 2007; 6:1102-1114.
10. Shukla S, Mishra A, Fu P, Maclennan GT, Resnick MI, Gupta S. Upregulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 2005; 19:2042-2044.
11. Liu LZ, Fang JQ, Hu X, Shi X, Jiang BH. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 2005; 68:635-643.
12. Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ, Yang JS, et al. Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax-and Bcl-2-triggered mitochondrial pathway. Int J Oncol 2010; 36:1477-1484.
13. Amit B, Ning G, Zhuo Z, Young-Ok S, Senping C, Xin W, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther 2012; 11:132-142.
14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
15. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-2196.
16. Daniel M, Shean Huey N, Feng G, Ramaswamy G. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010; 5:29-33.
17. Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Extending survival of stage IV non-small-cell lung cancer. Semin Oncol 2014; 41:69-92.
18. Chen WS, Hou JN, Guo YB, Yang HL, Xie CM, Lin YC, She ZG. Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway. J Exp Clin Cancer Res 2011; 30:17.
19. Chen YL, Law PY, Loh HH. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 2005; 64: 8723-8730.
20. Yongseon C, Mee-Ja P, Mira P, Sun Seek M, Jaeyong Y, Chan K, et al. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small-cell lung cancer cells. Respirology 2009; 14:850-858.
21. Balsara BR, Jianming P, Yasuhiro M, Robert P, Andres KS, Hao W, et al. Frequent activation of AKT in non-small-cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25:2053-2059.
22. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol 2010; 632:23-32.
23. Park JK, Park SK, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol 2010; 36:181-192.
24. Balsara BR, Pei J, Mitsuuchi Y, Page R, Kleinszanto A, Wang H, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25:2053-2059.
25. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004; 170:1088-1094.
26. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254:274-277.
27. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84:5034-5037.
28. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase. Cell 1995; 81:727-736.
29. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 2014; 90:197-207.
30. West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book 2013; 138:663-671.
31. Ipsita P, Mahitosh M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012; 33:1441-1458.
32. Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan J, et al. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKTinduced upregulation of MMP2/MMP9. Int J Oncol 2015; 47:690-700.
33. Jun H, Qing X, Min W, Chongyong L, Xu Q, Zhumei S, et al Oral administration of apigenin inhibits metastasis through AKT/P70S6K1/MMP-9 pathway in orthotopic ovarian tumor modelInt J Mol Sci 2012 13 7271-7282
34. Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao Y, Liu Q. TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res 2014; 26:410-417.
35. Shih Y, Chen P, Wu C, Jeng Y, Wang C. Alpha-chaconine-reduced metastasis involves a PI3K/Akt signaling pathway with downregulation of NF-B in human lung adenocarcinoma A549 cells. J Agric Food Chem 2007; 55:11035-11043.
36. C DA, A DR, C P, A M, H BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789.
37. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95:11211-11216.
38. Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and-insensitive mechanisms. J Biol Chem 1997; 272:7713-7719.
39. Zhou YF, Luo F, Huan-Huan FU, Xiao JW, Liao J. Inhibitory mechanisms of apigenin on aminopeptidase N of lung cancer cells. Med Pharm J Chin People Liberation Army 2015; 27:21-24.
40. Li RB, Yang JS. Inhibitory effect of apigenin against migration and invasion of human lung cancer A549 cells and the related mechanism. Acad J Second Mil Med Univ 2015; 36:878-882.
41. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61:3986-3997.
42. Massion PP, Taflan PM, Yu S, Rahman SMJ, Pinar Y, Bashar S, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004; 170:1088-1094.
43. Albert JM, Kim KW, Cao C, Bo L. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006; 5:1183-1189.
44. Debashis S, Reid AHM, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15:4799-4805.
45. Garcia-Echeverria C, Sellers W. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27:5511-5526.
46. Susan H, O'Byrne KJ, Kathy G. Strategies for co-targeting the PI3K/AKT/ mTOR pathway in NSCLC. Cancer Treat Rev 2013; 40:445-456.
47. Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009; 21:470-476.
48. Khasigov PZ, Podobed OV, Gracheva TS, Salbiev KD, Grachev SV, Berezov TT. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry 2003; 68:711-717.
49. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18:1135-1149.
50. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small-cell lung cancer. J Pathol 2000; 190:150-156.
51. Agnès NL, Maud J, Erik M. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008; 19:52-60.
52. Lei N, Yun F, Huanying W, Qinyun M, Liang F, Yanrong Q, et al. Angiotensin-(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol Rep 2012; 27:783-790.
53. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Eur J Biochem 1980; 107:519-527.
54. Abbas S, Andrei O, Zhi Wei Y, Bin Z, Modarressi MH, Billadeau DD, et al. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005; 334:1365-1373.
55. Qifei Z, Ying H, Feng S, Yizheng W. Polarized regulation of glycogen synthase kinase-3 is important for glioma cell invasion. PLoS One 2013; 8: e81814-e81814.
56. Wang WL, Hong TM, Chang YL,Wu CT, Pan SH, Yang PC. Phosphorylation of LCRMP-1 by GSK3 promotes filopoda formation, migration and invasion abilities in lung cancer cells. PloS One 2012; 7:e31689.
57. Wei L, Yao Y, Zhao K, Huang Y, Zhou Y, Zhao L, et al. Oroxylin A inhibits invasion and migration through suppressing ERK/GSK3 signaling in snailexpressing nonsmallcell lung cancer cells. Mol Carcinog 2016; 55:2121-2134.
58. Akiko S, Michiko S, Naoki Y, Shingo K. Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas. Int J Clin Exp Pathol 2014; 7:3312-3317.
59. Soma V, Chanlu X, Mu Y, Yuting S, Ulla S, Paul S, et al. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2 via AKT in prostate cancer cells. Oncotarget 2014; 5:6289-6299.
60. Wen X, Zhu J, Dong L, Chen Y. The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer. Med Oncol 2014; 31:1-12.
61. Singh M, Cowell L, Seo S, O'Neill G, Golemis E. Molecular basis for HEF1/ NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 2007; 48:54-72.
62. Eugene I, Singh MK, Plotnikova OV, Nadezhda T, Little JL, Serebriiskii IG, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res 2009; 69:7198-7206.
63. Lucas JT Jr, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 2010; 29:4449-4459.
64. Singh MK, Eugene I, Klein-Szanto AJ, Egleston BL, Marina W, Golemis EA. Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res 2010; 70:8907-8916.
65. Chang JX, Gao F, Zhao GQ, Zhang GJ. Expression and clinical significance of NEDD9 in lung tissues. Med Oncol 2012; 29:2654-2660.
66. Kim M, Gans J, Nogueira C, Wang A, Paik J, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006; 125:1269-1281.
67. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006; 25:7282.
68. O'Neill GM, Sachiko S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 2007; 67:8975-8979.